ELZONRIS (tagraxofusp-erzs) is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.

Please See Full Prescribing Information, including Boxed Warning for Capillary Leak Syndrome


ORSERDU (elacestrant) is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR-1 mutated advanced or metastatic breast cancer, following at least one line of endocrine therapy.


Learn More

Our Products & Pipeline

At Stemline, we are committed to applying our scientific leadership to transform the lives of people with cancer. We are focused on the development of a broad pipeline of innovative, transformative therapies in oncology.


Learn More

Stemline News & Media

Stemline is part of the Menarini Group, a leading international pharmaceutical and diagnostics company, with a turnover of over $4 billion and over 18,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia.

Learn More